Acquisition synergies TherOx is part of ZOLL Medical Corporation, presenting an opportunity to align SSO2 Therapy with ZOLL’s existing cardiovascular product ecosystem and sales channels for cross-sell and bundled offerings.

AMI focus expansion TherOx targets acute myocardial infarction patients with a one-time 60-minute SSO2 treatment post-PCI, indicating potential fit with hospital cath labs and interventional cardiology programs seeking enhanced infarct size reduction and improved patient outcomes.

Clinical alignment SSO2 Therapy aligns with current interventional cardiology guidelines, suggesting high relevance for hospital procurement teams prioritizing evidence-based, guideline-consistent technologies to improve revascularization outcomes.

SMB to mid-market potential With 11-50 employees and revenue in the low millions, TherOx is positioned for targeted hospital systems and regional health networks; consider pilot programs with mid-size hospitals and ASC networks to drive adoption.

Sales motion opportunities Leverage ZOLL’s established sales force, clinical education resources, and training capabilities to accelerate adoption, plus potential for combined financing or service packages to support implementation and aftercare.